Litcius/Paper detail

LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)

J-P. Machiels, Yungan Tao, Barbara Burtness, M. Tahara, D. Rischin, G.V. Alves, I.P. Figueiredo Lima, B.G.M. Hughes, Y. Pointreau, S. Aksoy, Simon Laban, R. Greil, M. Burian, M. Hetnal, L.F. Licitra, R. Swaby, Y. Zhang, B. Gumuscu, B. Bidadi, L.L. Siu

2022Annals of Oncology91 citationsDOI

Topics & Concepts

MedicinePembrolizumabHead and neck squamous-cell carcinomaPlaceboOncologyHead and neckHead and neck cancerPhases of clinical researchBasal cellInternal medicineRadiation therapyClinical trialSurgeryCancerImmunotherapyPathologyAlternative medicineCancer Immunotherapy and BiomarkersRadiopharmaceutical Chemistry and ApplicationsHead and Neck Cancer Studies
LBA5 Primary results of the phase III KEYNOTE-412 study: Pembrolizumab (pembro) with chemoradiation therapy (CRT) vs placebo plus CRT for locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) | Litcius